| | | | | | | | | | | | | | | Three Months Ended June 30, | | Six Months Ended June 30, | | | 2023 | | 2022 | | 2023 | | 2022 | Collaborative revenue | | | | | | | | | | | | | CSL Vifor (KORSUVA injection profit sharing) | | $ | 5,410 | | $ | 8,003 | | $ | 8,160 | | $ | 8,003 | Total collaborative revenue | | $ | 5,410 | | $ | 8,003 | | $ | 8,160 | | $ | 8,003 | Commercial supply revenue | | | | | | | | | | | | | CSL Vifor* (KORSUVA injection) | | $ | 1,400 | | $ | — | | $ | 4,591 | | $ | 4,790 | Total commercial supply revenue | | $ | 1,400 | | $ | — | | $ | 4,591 | | $ | 4,790 | Royalty revenue | | | | | | | | | | | | | CSL Vifor (Kapruvia ex U.S.) | | $ | 123 | | $ | — | | $ | 248 | | $ | — | Total royalty revenue | | $ | 123 | | $ | — | | $ | 248 | | $ | — | License and milestone fees | | | | | | | | | | | | | Vifor Fresenius Medical Care Renal Pharma Ltd. | | $ | — | | $ | 15,000 | | $ | — | | $ | 15,000 | Total milestone and fees | | $ | — | | $ | 15,000 | | $ | — | | $ | 15,000 | Clinical compound revenue | | | | | | | | | | | | | Maruishi | | $ | — | | $ | — | | $ | 99 | | $ | — | Total clinical compound revenue | | $ | — | | $ | — | | $ | 99 | | $ | — |
_____________________________ * Includes amounts earned from Vifor International prior to Vifor International’s assignment of its rights and obligations to Vifor Fresenius Medical Care Renal Pharma Ltd. in May 2022.
|